{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+plus+enzalutamide",
    "query": {
      "intervention": "Placebo plus enzalutamide"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 24,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+plus+enzalutamide&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-21T14:02:24.405Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07028853",
      "title": "This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration Sensitive Prostate Cancer (mCSPC)",
        "Hormone Sensitive Prostate Cancer",
        "Prostate Cancer",
        "Cancer of the Prostate"
      ],
      "interventions": [
        {
          "name": "Mevrometostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1000,
      "start_date": "2025-09-28",
      "completion_date": "2034-12-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 124,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 87 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07028853"
    },
    {
      "nct_id": "NCT06120491",
      "title": "Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Saruparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "18 Years to 130 Years · Male only"
      },
      "enrollment_count": 1898,
      "start_date": "2023-11-21",
      "completion_date": "2031-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 71,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 63 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06120491"
    },
    {
      "nct_id": "NCT02677896",
      "title": "A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Hormone Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1150,
      "start_date": "2016-03-09",
      "completion_date": "2024-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 34,
      "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 30 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02677896"
    },
    {
      "nct_id": "NCT02319837",
      "title": "Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hormone Sensitive Prostate Cancer",
        "Prostate Cancer",
        "Cancer of the Prostate"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (No longer applicable in Open Label study period)",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Open Label",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1068,
      "start_date": "2014-12-17",
      "completion_date": "2026-09-19",
      "has_results": true,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 77,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02319837"
    },
    {
      "nct_id": "NCT06629779",
      "title": "A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PF-06821497",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 900,
      "start_date": "2024-10-22",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 43,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 28 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06629779"
    },
    {
      "nct_id": "NCT02203695",
      "title": "Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "SRT",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 86,
      "start_date": "2015-03-28",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 9,
      "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Lafayette, Indiana + 6 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02203695"
    },
    {
      "nct_id": "NCT05700903",
      "title": "Contributions to Hypertension With Androgen Deprivation Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Androgen Deprivation Therapy",
        "Prostate Cancer",
        "Hypertension",
        "Autonomic Dysfunction",
        "Renal Disease"
      ],
      "interventions": [
        {
          "name": "Gonadotropin Releasing Hormone Agonists (GNRH)",
          "type": "DRUG"
        },
        {
          "name": "Androgen receptor (AR) inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2023-09-20",
      "completion_date": "2025-07-16",
      "has_results": true,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05700903"
    },
    {
      "nct_id": "NCT05726292",
      "title": "A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Relacorilant",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Sugar Pill)",
          "type": "OTHER"
        },
        {
          "name": "Androgen Deprivation Therapy",
          "type": "OTHER"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2025-01-06",
      "completion_date": "2028-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05726292"
    },
    {
      "nct_id": "NCT04237584",
      "title": "A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide during Lead-in Period",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Enzalutamide followed by Radium-223/Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Enzalutamide followed by Placebo/Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide during Lead-in Period",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Darolutamide followed by Radium-223/Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Darolutamide followed by Placebo/Darolutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MANA RBM",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 23,
      "start_date": "2020-06-30",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 1,
      "location_summary": "Myrtle Beach, South Carolina",
      "locations": [
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04237584"
    },
    {
      "nct_id": "NCT02407054",
      "title": "A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "LY3023414",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 142,
      "start_date": "2015-04-29",
      "completion_date": "2020-04-16",
      "has_results": true,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-09-21T14:02:24.405Z",
      "location_count": 36,
      "location_summary": "Homewood, Alabama • Fayetteville, Arkansas • Marina del Rey, California + 31 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Marina del Rey",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02407054"
    }
  ]
}